Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GSK3B | P49841 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.56 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.49 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazinecarboxamide SCHEMBL22471895 | 0.87 | HDAC8 (0.52) | MAPTALDH1A1GSK3BKDM4ENOTUM | |
| SCHEMBL9720227 | 0.87 | MAPT (0.70) | MAPTALDH1A1GSK3BNOTUMCA1 | |
| SCHEMBL18292345 | 0.83 | RAB9A (0.63) | MAPTALDH1A1GSK3BNOTUMCA1 | |
| SCHEMBL28372775 | 0.81 | NPC1 (0.73) | MAPTALDH1A1KDM4ENOTUMCA1 | |
| SCHEMBL26071703 | 0.81 | NPC1 (0.73) | MAPTALDH1A1GSK3BCA1CA2 | |
| SCHEMBL2835233 | 0.79 | MAPT (0.60) | MAPTALDH1A1GSK3BNOTUMCA1 | |
| SCHEMBL223767 | 0.79 | MAPT (0.65) | MAPTALDH1A1GSK3BNOTUMCA1 | |
| SCHEMBL28820070 | 0.79 | GSK3B (0.72) | MAPTALDH1A1GSK3BKDM4ENOTUM | |
| SCHEMBL10401832 | 0.79 | MAPT (0.60) | MAPTALDH1A1GSK3BNOTUMCA1 | |
| SCHEMBL6600158 | 0.79 | MAPT (0.60) | MAPTALDH1A1GSK3BNOTUMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2025-08-14 | — | — | US | disclosed |
| EP-4526291-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | The Board of Regents of the University of Texas System (US) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023224371-A1 | NOVEL OXADIAZOLE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY DISEASES COMPRISING SAME | (주)셀로스바이오텍 | 2023-11-23 | — | — | WO | disclosed |
| WO-2023225327-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-109438433-B | Myricetin derivative containing amide oxadiazole, preparation method and application thereof | 贵州大学 | 2022-02-15 | — | — | CN | disclosed |
| EP-3943159-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | Kabushiki Kaisha Yakult Honsha (JP) | 2022-01-26 | — | — | EP | disclosed |
| CN-110627783-B | Preparation method of Schiff base containing carbazolyl and oxadiazolyl or thiadiazolyl | 陕西科技大学 | 2021-11-16 | — | — | CN | disclosed |
| CN-107216357-B | Preparation method of Mannich base containing ferrocenyl oxadiazolyl | 陕西科技大学 | 2020-02-21 | — | — | CN | disclosed |
| CN-110627783-A | Preparation method of Schiff base containing carbazolyl and oxadiazolyl or thiadiazolyl | 陕西科技大学 | 2019-12-31 | — | — | CN | disclosed |
| CN-109438433-A | A kind of myricetin derivative, the preparation method and the usage of amide containing oxadiazoles | 贵州大学 | 2019-03-08 | — | — | CN | disclosed |
| CN-107216357-A | A kind of preparation method of the cyclopentadienyl Tie oxadiazole base Mannich bases containing Er | 陕西科技大学 | 2017-09-29 | — | — | CN | disclosed |
| US-20150275076-A1 | Non-crystallizable Pi-conjugated Molecular Glass Mixtures, Charge Transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-10-01 | — | — | US | disclosed |
| US-20150275076-A1 | Non-crystallizable Pi-conjugated Molecular Glass Mixtures, Charge Transporting Molecular Glass Mixtures, Luminescent Molecular Glass Mixtures, or Combinations Thereof for Organic Light Emitting Diodes and other Organic Electronics and Photonics Applications | Molaire Consulting | 2015-10-01 | — | — | US | disclosed |
| WO-2015148327-A2 | PI-CONJUGATED SEMICONDUCTIVE ORGANIC GLASS MIXTURES FOR OLED AND OEDS | MOLAIRE CONSULTING LLC (US) | 2015-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169640-A1 | PRODUCTION METHOD OF QUINOLINECARBOXAMIDE DERIVATIVE OR PRODUCTION INTERMEDIATE THEREOF | BCKDK, CBR3, NQO2 | MAPT 3851/4885ALDH1A1 213/4885GSK3B 2301/4885 |
| US-20250257041-A1 | INDUCERS OF INTEGRATED STRESS RESPONSE TO TREAT CANCER | DDIT3, ATF4, EIF2AK3 | MAPT 3664/4885ALDH1A1 4205/4885GSK3B 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.